Skip to content

Study · Case report or series · n = 1 · 2026

4 results

Semaglutide-Induced Symptomatic Remission in Ulcerative Colitis.

Alqinai B, Adeniran O, Adekolu A, Gayam S

ACG case reports journal8 Apr 2026

PMID41959596 (opens in a new tab)PMCIDPMC13061526 (opens in a new tab)DOI10.14309/crj.0000000000002070 (opens in a new tab)PepBankPUB-41959596
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with left-sided ulcerative colitis and poorly controlled diabetes, clinical remission was reached by 8 weeks after semaglutide was started.

    In plain wordsOne woman with ulcerative colitis reached clinical remission by 8 weeks after starting semaglutide. One case cannot show semaglutide caused it.

    Peptide
    Semaglutide
    Outcome
    DecreaseClinical remission of ulcerative colitis
    Study

    n = 1

    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    After semaglutide initiation, she achieved clinical remission by 8 weeks
    1 context sentence
    Summary · context
    We report a 42-year-old woman with left-sided UC and poorly controlled diabetes who achieved remission after initiating semaglutide.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with ulcerative colitis, fecal calprotectin improved after semaglutide was started.

    In plain wordsIn one woman with ulcerative colitis, a stool marker of gut inflammation improved after she started semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseFecal calprotectin
    Study

    n = 1

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    with improved fecal calprotectin
    1 context sentence
    Summary · context
    We report a 42-year-old woman with left-sided UC and poorly controlled diabetes who achieved remission after initiating semaglutide.
  3. 03HumanCase report or seriesEfficacy outcome

    In a woman with ulcerative colitis and diabetes, metabolic parameters improved after semaglutide was started.

    In plain wordsIn one woman with ulcerative colitis and diabetes, metabolic measures improved after she started semaglutide.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedMetabolic parameters
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    metabolic parameters, and mucosal healing on follow-up colonoscopy.
    1 context sentence
    Summary · context
    We report a 42-year-old woman with left-sided UC and poorly controlled diabetes who achieved remission after initiating semaglutide.
  4. 04HumanCase report or seriesEfficacy outcome

    In a woman with ulcerative colitis, follow-up colonoscopy showed mucosal healing after semaglutide was started.

    In plain wordsIn one woman with ulcerative colitis, a follow-up colonoscopy showed the gut lining had healed after she started semaglutide.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedMucosal healing on colonoscopy
    Study

    n = 1

    Outcome group
    Gastrointestinal function · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    mucosal healing on follow-up colonoscopy.
    1 context sentence
    Summary · context
    We report a 42-year-old woman with left-sided UC and poorly controlled diabetes who achieved remission after initiating semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.